Medicare spending analysis for Interventional Pain Management providers
Interventional Pain Management accounts for $3.3B in Medicare payments across 16.2K providers.
The specialty's average markup of 5.0x is above the overall Medicare average of 3.77x.
AI-generated analysis based on Medicare payment data.
Providers in this specialty flagged by the ML v2 fraud detection model
| Year | Payments | Services | Providers | YoY Change |
|---|---|---|---|---|
| 2014 | $369.1M | 9.9M | 1.8K | — |
| 2015 | $359.7M | 9.1M | 1.7K | -2.5% |
| 2016 | $336.6M | 7.2M | 1.6K | -6.4% |
| 2017 | $346.9M | 7.8M | 1.6K | +3.1% |
| 2018 | $350.0M | 8.3M | 1.6K | +0.9% |
| 2019 | $352.5M | 8.3M | 1.6K | +0.7% |
| 2020 | $309.1M | 7.3M | 1.6K | -12.3% |
| 2021 | $339.5M | 7.4M | 1.6K | +9.8% |
| 2022 | $294.9M | 6.7M | 1.5K | -13.1% |
| 2023 | $276.4M | 6.4M | 1.5K | -6.3% |
| # | Provider | State | Payments | Services | Avg/Service |
|---|---|---|---|---|---|
| 1 | Charles Sisson | CO | $2.6M | 221.2K | $11.76 |
| 2 | Timothy Groth | NY | $2.4M | 28.1K | $84.01 |
| 3 | Alexey Ryskin | WA | $2.3M | 24.7K | $91.21 |
| 4 | Vipul Mangal | MD | $2.2M | 18.8K | $116.73 |
| 5 | Daniel Kendall | VA | $2.2M | 12.0K | $180.08 |
| 6 | Joshua Mintz | TX | $2.2M | 183.4K | $11.77 |
| 7 | Clifford Baker | AZ | $1.7M | 50.4K | $34.31 |
| 8 | Randall Oliver | IN | $1.5M | 13.4K | $115.21 |
| 9 | Scott Fuchs | FL | $1.5M | 85.1K | $17.41 |
| 10 | Zdenko Korunda | FL | $1.4M | 27.6K | $49.66 |
| 11 | Donald Erb | FL | $1.3M | 86.9K | $15.50 |
| 12 | Steven Kozmary | NV | $1.3M | 15.6K | $85.42 |
| 13 | Josif Borovic | CA | $1.2M | 13.7K | $85.85 |
| 14 | Chheany Ung | VA | $1.2M | 74.6K | $15.42 |
| 15 | Jonathan Daitch | FL | $1.1M | 17.9K | $60.19 |
| 16 | Joseph Cartwright | FL | $1.1M | 17.3K | $61.62 |
| 17 | Emmanuel Gage | GA | $1.1M | 14.9K | $71.27 |
| 18 | Edward Rubin | NY | $1.1M | 11.8K | $89.25 |
| 19 | Daniel Morris | OK | $1.0M | 36.5K | $28.42 |
| 20 | Dharam Mann | NJ | $1.0M | 68.3K | $15.12 |
| 21 | Edward Kowlowitz | IN | $1.0M | 12.0K | $85.21 |
| 22 | Daniel Beirne | FL | $1.0M | 19.2K | $52.71 |
| 23 | Alan Miller | FL | $984.2K | 20.0K | $49.19 |
| 24 | Ellen Lin | TX | $943.8K | 8.7K | $108.98 |
| 25 | Fabian Ramos | FL | $940.6K | 12.6K | $74.71 |
| Code | Description | Payments | Services | Avg/Service |
|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | $55.2M | 601.3K | $91.82 |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | $25.6M | 398.7K | $64.23 |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | $17.1M | 103.6K | $165.11 |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | $14.6M | 46.4K | $315.00 |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | $10.7M | 73.3K | $145.89 |
| 62323 | Injection of substance into lower spine canal using imaging guidance | $10.7M | 76.2K | $140.27 |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | $9.7M | 80.8K | $119.86 |
| 80307 | Testing for presence of drug, by chemistry analyzers | $9.4M | 157.1K | $60.08 |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | $7.6M | 49.7K | $152.16 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | $6.6M | 34.6K | $191.99 |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | $5.7M | 48.2K | $117.86 |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | $5.4M | 68.6K | $79.46 |
| 63650 | Insertion of spinal neurostimulator electrode array through skin | $5.0M | 10.0K | $497.73 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | $4.9M | 20.3K | $239.98 |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | $4.8M | 404.5K | $11.76 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | $4.3M | 38.3K | $110.95 |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | $4.0M | 28.7K | $139.91 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | $3.9M | 25.8K | $151.90 |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | $3.7M | 24.6K | $152.30 |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | $3.5M | 48.9K | $71.73 |
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.